Emory Corporate Governance and Accountability Review

ECGAR PerspectivesVolume 5

Don't Be Fooled: E-Cigarette Companies and the Revitalized Attack on America's Youth

Wrenica Archibald | 5 Emory Corp. Governance and Accountability Rev. Perspectives 101 (2018)

This Perspective will try to first dispel the misconception that e-cigarettes are harmless by introducing current research on their dangers, especially with regard to teenagers. It will awaken young consumers to the marketing tactics of tobacco companies who rely on friendly flavors to re-attract teenagers to smoke. It will also present viable legal solutions that have proven successful in the past in curtailing tobacco companies’ attempts to seduce America’s youth to smoke. Ultimately, this argument will impress upon Congress and the FDA the necessity of regulating e-cigarettes as traditional cigarettes by: 1) prohibiting the flavoring of e-cigarettes, 2) prohibiting advertisement geared toward young people, and 3) initiating a media campaign informing teenagers of the dangers of e-cigarettes.

Read more »

Biohazard: The Medical Loss Ratio as Constitutionally Permissible Garbage (and How to Dispose of It)

Joseph Erkenbrack | 5 Emory Corp. Governance and Accountability Rev. Perspectives 109 (2018)

Since the Affordable Care Act (ACA) became law in 2010, it has been subject to political and constitutional scrutiny. While most critics have focused on the expansion of Medicaid and the individual mandate, the rest of the bill is by no means universally praised. One such controversial provision is the Medical Loss Ratio (MLR). Congress crafted the MLR with the purpose to improve patient care and reduce unnecessary administrative spending and excessive corporate profits. Those companies which do not, in a given year, spend the mandated amount on patient care, as opposed to other expenses, must make up the difference by providing a rebate to their policyholders. The purpose of the rebate is both to provide an incentive for insurance companies to comply with government regulations regarding revenue apportionment and compensate consumers who have been “shortchanged.” This Perspective will (1) show that the MLR is constitutional, (2) but that it is nevertheless poor policy, and (3) suggest some alternatives for Congress to consider should it repeal and replace the ACA.

Read more »

Citizen Petitions: A Process Hijacked by Big Pharma?

Eric Evans | 5 Emory Corp. Governance and Accountability Rev. Perspectives 115 (2018)

In response to some of the most egregious abuses of the citizen petition process, pharmaceutical manufacturers who raise concerns via the petition process that relate to their own product’s formulation, delivery system, or any other aspect should be estopped from continuing to market and sell their product as is. If a drug manufacturer files a 505(q) petition, the FDA should force the filing manufacturer to comply in regards to their own products with the suggested requirements they make for the generic competition.

Read more »

Nursing Home Fraud: Responsible Ways to Increase Profits in Nursing Homes

Regine Lewis | 5 Emory Corp. Governance and Accountability Rev. Perspectives 121 (2018)

The government is working tirelessly to deter healthcare fraud in Skilled Nursing Facilities (“SNF”). The government is increasingly holding SNF’s liable for overbilling Medicare for medically unnecessary services and billing for services that were not provided. The government believes that SNF’s are committing Medicare fraud to increase profits in its facilities. To understand nursing home fraud, it is necessary to evaluate the False Claims Act (which is the leading body of law that SNF’s are held liable under), how SNF’s are reimbursed by Medicare, and SNF false claims liability for Medicare fraud. This Perspective will then offer ways for SNF’s to increase profits legally and responsibly.

Read more »

Big Pharma Takes on Marijuana Legalization: The Synthetic Marijuana vs. Botanical Marijuana Paradox

Katharine Pickle | 5 Emory Corp. Governance and Accountability Rev. Perspectives 127 (2018)

With marijuana remaining an illegal, Schedule I drug at the federal level, many legal questions and oddities surround the implications of federal law on state marijuana legalization. One point of apparent inconsistency is that while botanical marijuana continues to be highly disputed, synthetic versions of marijuana are legally produced and marketed nationwide by Big Pharma corporations. As the door continues to open for marijuana as a legal medical alternative, Big Pharma may be faced with a significant competitive adversary. There is some evidence to suggest that Big Pharma will respond by using its deep pockets not only to prevent legalization, but also to prevent research that would inform consumers of the beneficial effects of botanical marijuana vs. its synthetic counterpart.

Read more »